Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings

Abstract Background In the absence of head-to-head trials, comprehensive evidence comparing onset of efficacy of novel agents for acute treatment of migraine is lacking. This study aimed to explore the relative efficacy of lasmiditan (serotonin [5-hydroxytryptamine] 1F receptor agonist) versus rimeg...

Full description

Bibliographic Details
Main Authors: Pepa Polavieja, Mark Belger, Shiva Kumar Venkata, Stefan Wilhelm, Erin Johansson
Format: Article
Language:English
Published: BMC 2022-07-01
Series:The Journal of Headache and Pain
Subjects:
Acute treatments
Efficacy
Gepants
Lasmiditan
Rimegepant
Ubrogepant
Online Access:https://doi.org/10.1186/s10194-022-01440-w

Internet

https://doi.org/10.1186/s10194-022-01440-w

Similar Items